An indoxyl compound 5-bromo-4-chloro-3-indolyl 1,3-diacetate, CAC-0982, suppresses activation of Fyn kinase in mast cells and IgE-mediated allergic responses in mice

Toxicology and Applied Pharmacology

Volumn 285, Issue 3, 2015, Pages 179-186

  Lee, Jun Ho ^a,b   Kim, Tae Hyung ^c   Kim, Hyuk Soon ^a   Kim, A Ram ^a   kim, Do Kyun ^a,d   Nam, Seung Taek ^a   Kim, Hyun Woo ^a   Park, Young Hwan ^a   Her, Erk ^a   Park, Yeong Min ^a   Kim, Hyung Sik ^c   Kim, Young Mi ^e   Choi, Wahn Soo ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Duksung Women's University   (South Korea)

Author keywords

5 Bromo 4 chloro 3 indolyl 1,3 diacetate CAC 0982; Allergy; Fyn kinase; Mast cells; Syk kinase

Indexed keywords

5 BROMO 4 CHLORO 3 INDOLYL 1,3 DIACETATE; ANTIALLERGIC AGENT; INTERLEUKIN 4; LAT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN KINASE FYN; PROTEIN KINASE SYK; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CAC-0982; IMMUNOGLOBULIN E; INDOLE DERIVATIVE; INDOXYL; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEGRANULATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MAST CELL; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; DRUG EFFECTS; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

MURINAE; MUS;

ANIMALS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INDOLES; INTERLEUKIN-4; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAST CELLS; MICE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-FYN; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928741798     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.04.009     Document Type: Article

References (48)

1. Akdis C.A. The pathogenesis of asthma. European Academy of Allergy and Clinical Immunology 2013, 28-31. C.A. Akdis (Ed.).
2. Beaven M.A. Our perception of the mast cell from Paul Ehrlich to now. Eur. J. Immunol. 2009, 39:11-25.
3. Begin P., Nadeau K.C. Epigenetic regulation of asthma and allergic disease. Allergy Asthma Clin. Immunol. 2014, 10:27.
4. Bischoff S.C. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat. Rev. Immunol. 2007, 7:93-104.
5. Bradding P. Novel approaches to the inhibition of mast cells in allergic disease. Clin. Exp. Allergy 2008, 38:704-708.
6. Broide D.H. Molecular and cellular mechanisms of allergic disease. J. Allergy Clin. Immunol. 2001, 108:S65-S71.
7. Burks A.W., et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J. Allergy Clin. Immunol. 2013, 131:1288-1296.
8. Carter A.B., et al. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am. J. Respir. Cell Mol. Biol. 1999, 20:751-758. G.W.,.
9. Castillo J., Dimov V. Investigational drugs for the treatment of allergic rhinitis. Expert Opin. Investig. Drugs 2014, 23:823-836.
10. Duan W., Wong W.S. Targeting mitogen-activated protein kinases for asthma. Curr. Drug Targets 2006, 7:691-698.
11. El-Qutob D., et al. Recent advances in immunotherapy for allergic diseases. Recent Pat. Inflamm. Allergy Drug Discov. 2014, 8:24-35.
12. Frossi B., et al. Selective activation of Fyn/PI3K and p38 MAPK regulates IL-4 production in BMMC under nontoxic stress condition. J. Immunol. 2007, 178:2549-2555.
13. Galli S.J., et al. The development of allergic inflammation. Nature 2008, 454:445-454.
14. Gilfillan A.M., Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol. Rev. 2009, 228:149-169.
15. Gomez G., et al. Impaired FcepsilonRI-dependent gene expression and defective eicosanoid and cytokine production as a consequence of Fyn deficiency in mast cells. J. Immunol. 2005, 175:7602-7610.
16. Hayen S.M., et al. Novel immunotherapy approaches to food allergy. Curr. Opin. Allergy Clin. Immunol. 2014, 14:549-556.
17. Holgate S.T. New strategies with anti-IgE in allergic diseases. World Allergy Organ. J. 2014, 7:17.
18. Holgate S.T., Polosa R. Treatment strategies for allergy and asthma. Nat. Rev. Immunol. 2008, 8:218-230.
19. Ingley E. Functions of the Lyn tyrosine kinase in health and disease. Cell. Commun. Signal 2012, 10:21.
20. Ishizuka T., et al. Mast cell tumor necrosis factor alpha production is regulated by MEK kinases. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6358-6363.
21. Jensen B.M., et al. Generation, isolation, and maintenance of rodent mast cells and mast cell lines. Curr. Protoc. Immunol. 2006, (Chapter 3, Unit 3 23).
22. Juergensmeyer M.A., Gingras B.A., Restaino L., Frampton E.W. A selective chromogenic agar that distinguishes Bacillus anthracis from Bacillus cereus and Bacillus thuringiensis. J. Food Prot. 2006, 69:2002-2006.
23. Kawakami T., Galli S.J. Regulation of mast-cell and basophil function and survival by IgE. Nat. Rev. Immunol. 2002, 2:773-786.
24. Kim J.W., et al. Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo. Biochem. Pharmacol. 2009, 77:1506-1512.
25. Kopp M.V. Omalizumab: anti-IgE therapy in allergy. Curr. Allergy Asthma Rep. 2011, 11:101-106.
26. Lee J.H., et al. Phospholipase D2 acts as an essential adaptor protein in the activation of Syk in antigen-stimulated mast cells. Blood 2006, 108:956-964.
27. Lee J.H., et al. Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. J. Allergy Clin. Immunol. 2008, 121:1225-1231.
28. Lee J.H., et al. The Src family kinase Fgr is critical for activation of mast cells and IgE-mediated anaphylaxis in mice. J. Immunol. 2011, 187:1807-1815.
29. Lorentz A., et al. Role of activator protein 1, nuclear factor-kappaB, and nuclear factor of activated T cells in IgE receptor-mediated cytokine expression in mature human mast cells. J. Allergy Clin. Immunol. 2003, 111:1062-1068.
30. Lu Y., et al. Saucerneol F inhibits tumor necrosis factor-alpha and IL-6 production by suppressing Fyn-mediated pathways in FcepsilonRI-mediated mast cells. Food Chem. Toxicol. 2013, 59:696-702.
31. Masuda E.S., Schmitz J. Syk inhibitors as treatment for allergic rhinitis. Pulm. Pharmacol. Ther. 2008, 21:461-467.
32. Metzger H. The high affinity receptor for IgE, FcepsilonRI. Novartis Found. Symp. 2004, 257:51-59.
33. Mocsai A., et al. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 2010, 10:387-402.
34. Okudaira H., et al. A study of the rat passive cutaneous anaphylaxis (PCA) reaction for the assay of mouse IgE antibody. J. Immunol. Methods 1980, 33:369-377.
35. Ozawa K., et al. Ca(2+)-dependent and Ca(2+)-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with Ca2+ and purified isozymes in washed permeabilized cells. J. Biol. Chem. 1993, 268:1749-1756.
36. Park K.L., et al. 4-Chlorotetrazolo[1,5-a]quinoxaline inhibits activation of Syk kinase to suppress mast cells in vitro and mast cell-mediated passive cutaneous anaphylaxis in mice. Toxicol. Appl. Pharmacol. 2011, 257:235-241.
37. Parravicini V., et al. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat. Immunol. 2002, 3:741-748.
38. Pohanka M., Drtinova L. Spectrophotometric methods based on 2,6-dichloroindophenol acetate and indoxylacetate for butyrylcholinesterase activity assay in plasma. Talanta 2013, 106:281-285.
39. Poole J.A., et al. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J. Allergy Clin. Immunol. 2005, 115:S376-S385.
40. Rivera J., Gilfillan A.M. Molecular regulation of mast cell activation. J. Allergy Clin. Immunol. 2006, 117:1214-1225.
41. Roth K., et al. Positive and negative regulatory mechanisms in high-affinity IgE receptor-mediated mast cell activation. Arch. Immunol. Ther. Exp. (Warsz) 2008, 56:385-399.
42. Sheehan M.P., et al. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Br. J. Dermatol. 1993, 129:431-436.
43. Stone K.D., et al. IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol. 2010, 125:S73-S80.
44. Theoharides T.C., Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann. N. Y. Acad. Sci. 2006, 1088:78-99.
45. Ujike A., et al. Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J. Exp. Med. 1999, 189:1573-1579.
46. Voehringer D. Protective and pathological roles of mast cells and basophils. Nat. Rev. Immunol. 2013, 13:362-375.
47. Wang X., et al. Shikonin, a constituent of Lithospermum erythrorhizon exhibits anti-allergic effects by suppressing orphan nuclear receptor Nr4a family gene expression as a new prototype of calcineurin inhibitors in mast cells. Chem. Biol. Interact. 2014, 224:117-127.
48. Yu M., et al. Scaffolding adapter Grb2-associated binder 2 requires Syk to transmit signals from FcepsilonRI. J. Immunol. 2006, 176:2421-2429.